Key facts
- Tempero Bio’s last known valuation is $148.0M (Nov 2025).
- It has raised $88.6M across 1 recorded rounds; the latest was Later Stage VC ($77.0M) in Oct 2024.
- Notable investors include Khosla Ventures, 8VC, Aditum Bio, Incubateur Impulse, Nxera Pharma — 7 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Tempero Bio
Funding rounds
1 roundsAbout Tempero Bio
Developer of transformative therapies designed for treating and preventing substance use disorders. The company offers a potent, orally available metabotropic glutamate receptor negative allosteric modulator (NAM) that regulates neural signaling, with investigations targeting conditions such as cocaine and alcohol use disorders, enabling doctors to support patients in overcoming dependencies and enhancing overall health outcomes.
- Sector
- Healthcare
- HQ
- Oakland, CA, United States
- Founded
- 2020
- Employees
- 5
- Website
- temperobio.com/
- Ownership
- Privately Held (backing)
Tempero Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tempero Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tempero Bio in its N-PORT filings yet. We sweep new filings monthly.